Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

YM BioSciences rises on PhI/II results showing promise for JAK1/JAK2 inhibitor for myelofibrosis

This article was originally published in Scrip

Executive Summary

YM BioSciences reported updated Phase I/II data for its oral JAK1/JAK2 inhibitor CYT387 as a potential treatment for myelofibrosis (MF) in a 12 December poster session at the annual meeting of the American Society of Hematology in San Diego.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC015540

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel